These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38761584)

  • 1. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
    Li H; Cai X; Yang X; Zhang X
    Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
    Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
    Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
    Vicente ATS; Salvador JAR
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
    Skalniak L; Surmiak E; Holak TA
    Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
    Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing AS1411 for constructing ANM-PROTACs.
    Fu X; Li J; Chen X; Chen H; Wang Z; Qiu F; Xie D; Huang J; Yue S; Cao C; Liang Y; Lu A; Liang C
    Cell Chem Biol; 2024 Jul; 31(7):1290-1304.e7. PubMed ID: 38657608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide activators of the p53 tumor suppressor.
    Zhan C; Lu W
    Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
    Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
    Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.